Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat

Moderna shares sank over 25% on Thursday as late-stage trial data for its personalized melanoma vaccine, developed with Merck triggered what analysts called a "sell-the-news" reaction after a ​months-...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。